Murriel Christopher L, Dowdy Steven F
Howard Hughes Medical Institute, Department of Cellular & Molecular Medicine, UCSD School of Medicine, La Jolla, CA 92093-0686, USA.
Expert Opin Drug Deliv. 2006 Nov;3(6):739-46. doi: 10.1517/17425247.3.6.739.
As the plasma membrane and blood-brain barrier selectively restrict the entry of most compounds into cells to < 500 Da, delivering macromolecules into cells was, until recently, little more than a goal. However, with significant effort to capitalise on therapeutic targets available in the post-genomic era, novel approaches for delivering therapeutic macromolecules are being rapidly developed. The discovery of small cationic peptides, termed peptide/protein transduction domains or cell-penetrating peptides, which cross biological membranes, has emerged as a venerable Trojan horse to transport large, biologically active molecules, such as peptides, proteins and oligonucleotides, into mammalian cells in vitro, as well as in preclinical models and clinical trials in vivo. This review discusses the implications of peptide/protein transduction domain-mediated delivery of macromolecules and their possible uses as important primary drug delivery agents.
由于质膜和血脑屏障会选择性地限制大多数化合物进入细胞,使其分子量小于500道尔顿,直到最近,将大分子递送至细胞内还仅仅是个目标而已。然而,随着人们为利用后基因组时代可得的治疗靶点付出巨大努力,递送治疗性大分子的新方法正在迅速发展。被称为肽/蛋白质转导结构域或细胞穿透肽的小阳离子肽的发现,已成为一种备受瞩目的“特洛伊木马”策略,可将诸如肽、蛋白质和寡核苷酸等大型生物活性分子在体外转运至哺乳动物细胞,也能在体内的临床前模型和临床试验中实现这一过程。本综述探讨了肽/蛋白质转导结构域介导的大分子递送的意义及其作为重要的初级药物递送剂的可能用途。